These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 1328554)
21. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990. Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351 [TBL] [Abstract][Full Text] [Related]
22. Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone. Visser MR; Rozenberg-Arska M; Beumer H; Hoepelman IM; Verhoef J Antimicrob Agents Chemother; 1991 May; 35(5):858-68. PubMed ID: 1854167 [TBL] [Abstract][Full Text] [Related]
23. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates. Ismaeel NA; Tayeb OS Microbios; 1993; 74(300):147-54. PubMed ID: 8396196 [TBL] [Abstract][Full Text] [Related]
24. In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria. Cohen MA; Huband MD; Mailloux GB; Yoder SL; Roland GE; Heifetz CL Diagn Microbiol Infect Dis; 1991; 14(5):403-15. PubMed ID: 1665775 [TBL] [Abstract][Full Text] [Related]
25. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin. Barry AL; Fuchs PC J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012 [TBL] [Abstract][Full Text] [Related]
26. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. Pillar CM; Aranza MK; Shah D; Sahm DF J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646 [TBL] [Abstract][Full Text] [Related]
27. Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria. Piddock LJ; Zhu M Antimicrob Agents Chemother; 1991 Nov; 35(11):2423-7. PubMed ID: 1666499 [TBL] [Abstract][Full Text] [Related]
28. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone. Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824 [TBL] [Abstract][Full Text] [Related]
29. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates. Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230 [TBL] [Abstract][Full Text] [Related]
30. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones. Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237 [TBL] [Abstract][Full Text] [Related]
31. Antimicrobial activity of DV-7751a, a new fluoroquinolone. Tanaka M; Hoshino K; Ishida H; Sato K; Hayakawa I; Osada Y Antimicrob Agents Chemother; 1993 Oct; 37(10):2112-8. PubMed ID: 8257132 [TBL] [Abstract][Full Text] [Related]
32. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Visalli MA; Bajaksouzian S; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669 [TBL] [Abstract][Full Text] [Related]
33. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065 [TBL] [Abstract][Full Text] [Related]
34. In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria. Louie A; Baltch AL; Ritz WJ; Smith RP Chemotherapy; 1991; 37(4):275-82. PubMed ID: 1665123 [TBL] [Abstract][Full Text] [Related]
35. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392 [TBL] [Abstract][Full Text] [Related]
36. Antibacterial activity of the new quinolone CI-960 (PD 127391) against clinical isolates at a major tertiary care center in Saudi Arabia. Qadri SM; Abo-Askar H; Ueno Y Chemotherapy; 1992; 38(2):92-8. PubMed ID: 1317281 [TBL] [Abstract][Full Text] [Related]
37. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA; Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564 [TBL] [Abstract][Full Text] [Related]
39. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Barry AL; Fuchs PC Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696 [TBL] [Abstract][Full Text] [Related]
40. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone. Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]